Across TCGA pan-cancer cohorts, CNN2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CNN2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in thyroid carcinoma (THCA), where higher CNN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CNN2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
THCA, LUAD, and STAD are the cancer types where CNN2 Mutation most reproducibly stratifies survival.